Dr Afsar Mian


  1. Ali S, Khan FA, Mian AA, and Afzal MS (2014). Seroprevalence of cytomegalovirus, herpes simplex virus and rubella virus among pregnant women in KPK province of Pakistan. J Infect Dev Ctries, 8(3), 389-390. doi:10.3855/jidc.3854. Link

  2. Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C, and Ruthardt M (2008). Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. Int J Cancer, 122(12), 2744-2752. doi:10.1002/ijc.23467. Link

  3. Haberbosch I, Rafiei A, Oancea C, Ottmann GO, Ruthardt M, and Mian AA (2016). BCR: a new target in resistance mediated by BCR/ABL-315I? Genes Cancer, 7(1-2), 36-46. doi:10.18632/genesandcancer.93. Link

  4. Khateb M, Ruimi N, Khamisie H, Najajreh Y, Mian AA, Metodieva A, . . . Mahajna J (2012). Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism. BMC Cancer, 12, 563. doi:10.1186/1471-2407-12-563. Link

  5. Legut M, Dolton G, Mian AA, Ottmann OG and Sewell AK (2018). CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. Blood, 131(3), 311-322. doi:10.1182/blood-2017-05-787598. Link

  6. Mian AA, Haberbosch I, Ottmann GO and Ruthardt M (2104). Transphosphorylation of Endogenous BCR Mediates the Effect of T315I on the Transformation Potential of BCR/ABL. Bloodjournal, 124(21), 4523. Link

  7. Mian AA, Metodieva A, Badura S, Khateb M, Ruimi N, Najajreh Y, . . . Ruthardt M (2012). Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. BMC Cancer, 12, 411. doi:10.1186/1471-2407-12-411. Link

  8. Mian AA, Metodieva A, Najajreh Y, Ottmann OG, Mahajna J and Ruthardt M (2012). p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica, 97(2), 251-257. doi:10.3324/haematol.2011.047191. Link

  9. Mian AA, Metodieva A, Najajreh Y, Serve H, Ottmann OG, Mahajna J and Ruthardt M (2010). The Degree of Response of Philadelphia Chromosome Positive Acute Lymphatic Leukemia to Allosteric Inhibition by GNF-2 Depends on the Presence of Either p185-BCR/ABL or p210-BCR/ABL. Bloodjournal, 116(21), 598. Link

  10. Mian AA, Oancea C, Zhao Z, Ottmann OG and Ruthardt M (2009). Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia, 23(12), 2242-2247. doi:10.1038/leu.2009.194. Link

  11. Mian AA, Rafiei A, Haberbosch I, Zeifman A, Titov I, Stroylov V, . . . Ruthardt M (2015). PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia, 29(5), 1104-1114. doi:10.1038/leu.2014.326. Link

  12. Mian AA, Rafiei A, Metodieva A, Haberbosch I, Zeifman A, Titov I, . . . Ruthardt M (2013). PF-114, a Novel Selective Pan BCR/ABL Inhibitor Targets The T315I and Suppress Models Of Advanced Ph+ ALL. Bloodjournal, 122(21), 3907.  Link

  13. Mian AA, Schull M, Oancea C, Najajreh Y, Mahajna J, Goldblum A, . . . Ruthardt M (2011). Targeting the Oligomerization of BCR/ABL by Membrane Permeable Competitive Peptides Inhibits the Proliferation of Philadelphia Chromosome Positive Leukemic Cells. The Open Hematology Journal, 5, 21-27. doi:10.2174/1874276901105010021. Link

  14. Mian AA, Schull M, Zhao Z, Oancea C, Hundertmark A, Beissert T, . . . Ruthardt M (2009). The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL. Leukemia, 23(9), 1614-1621. doi:10.1038/leu.2009.69. Link

  15. Oancea C, Ruster B, Brill B, Roos J, Heinssmann M, Bug G, Mian AA . . . Ruthardt M (2014). STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML. Genes Cancer, 5(11-12), 378-392. doi:10.18632/genesandcancer.39. Link

  16. Rafiei A, Mian AA, Doring C, Metodieva A, Oancea C, Thalheimer FB, . . . Ruthardt M (2015). The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia. PLoS Genet, 11(4), e1005144. doi:10.1371/journal.pgen.1005144. Link